2 окт. 2024 г. · FDA approval history for Keytruda (pembrolizumab) used to treat Melanoma, Metastatic, Non Small Cell Lung Cancer, Head and Neck Cancer, ...

11 мая 2017 г. · On May 10, 2017, the U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA®, Merck and Co., ...

13 авг. 2019 г. · The first approval came in June 2018. The FDA greenlit Keytruda for previously treated patients with recurrent metastatic cervical cancer whose ...

Pembrolizumab was approved for medical use in the United States in 2014. It is on the World Health Organization's List of Essential Medicines.

21 июн. 2024 г. · On June 17, the FDA approved the cancer immunotherapy drug, pembrolizumab (Keytruda®), combined with chemotherapy, for the treatment of adult ...

On January 26, 2023, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) for adjuvant treatment following resection and ...

On June 29, 2020, the Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck & Co.) for the first-line treatment of patients with unresectable ...

The FDA approved pembrolizumab on May 23, 2017, for the treatment of adult and pediatric patients with unresectable or metastatic, MSI-H, or dMMR solid tumors ...

On October 24, 2016, the FDA approved pembrolizumab for treatment of patients with mNSCLC whose tumors express PD‐L1 as determined by an FDA‐approved test.

On August 20, 2018, the Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck & Co., Inc.) in combination with pemetrexed and platinum as ...